Harindhanavudhi T, Takahashi T, Petryk A, Polly D
AACE Clin Case Rep. 2020; 6(6):e305-e310.
PMID: 33244490
PMC: 7685405.
DOI: 10.4158/ACCR-2020-0222.
Kocaoglu M, Eralp L, Bilen F, Civan M
Acta Orthop Traumatol Turc. 2020; 54(3):245-254.
PMID: 32442122
PMC: 7586764.
DOI: 10.5152/j.aott.2020.03.26.
Singer D, Johnston C
JB JS Open Access. 2019; 4(2):e0004.
PMID: 31334459
PMC: 6613849.
DOI: 10.2106/JBJS.OA.19.00004.
Tahaei S, Couasnay G, Ma Y, Paria N, Gu J, Lemoine B
Bone. 2017; 106:103-111.
PMID: 29032173
PMC: 5694354.
DOI: 10.1016/j.bone.2017.10.012.
Hissnauer T, Stiel N, Babin K, Rupprecht M, Hoffmann M, Rueger J
J Mater Sci Mater Med. 2017; 28(4):60.
PMID: 28213747
DOI: 10.1007/s10856-017-5868-9.
The use of recombinant morphogenic protein-2(rhBMP-2) in children undergoing revision surgery for persistent non-union.
Papanna M, Saldanha K, Kurian B, Fernandes J, Jones S
Strategies Trauma Limb Reconstr. 2016; 11(1):53-8.
PMID: 26984411
PMC: 4814389.
DOI: 10.1007/s11751-016-0251-9.
Computational modeling of bone fracture non-unions: four clinically relevant case studies.
Carlier A, Lammens J, Van Oosterwyck H, Geris L
In Silico Cell Tissue Sci. 2015; 2:1.
PMID: 26709368
PMC: 4684906.
DOI: 10.1186/s40482-015-0004-x.
Ilizarov bone transport as a treatment of congenital pseudarthrosis of the tibia: a long-term follow-up study.
Vanderstappen J, Lammens J, Berger P, Laumen A
J Child Orthop. 2015; 9(4):319-24.
PMID: 26266468
PMC: 4549345.
DOI: 10.1007/s11832-015-0675-7.
Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
Ndong J, Stevens D, Vignaux G, Uppuganti S, Perrien D, Yang X
J Bone Miner Res. 2014; 30(1):55-63.
PMID: 25043591
PMC: 4280331.
DOI: 10.1002/jbmr.2316.
Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.
Ndong J, Makowski A, Uppuganti S, Vignaux G, Ono K, Perrien D
Nat Med. 2014; 20(8):904-10.
PMID: 24997609
PMC: 4126855.
DOI: 10.1038/nm.3583.
Effectiveness of recombinant human bone morphogenetic protein-7 in the management of congenital pseudoarthrosis of the tibia: a randomised controlled trial.
Das S, Ganesh S, Pradhan S, Singh D, Mohanty R
Int Orthop. 2014; 38(9):1987-92.
PMID: 24827969
DOI: 10.1007/s00264-014-2361-7.
Congenital pseudarthrosis of the tibia: the results of an evolving protocol of management.
Nicolaou N, Ghassemi A, Hill R
J Child Orthop. 2014; 7(4):269-76.
PMID: 24432086
PMC: 3799925.
DOI: 10.1007/s11832-013-0499-2.
Masquelet's procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis.
Dohin B, Kohler R
J Child Orthop. 2013; 6(4):297-306.
PMID: 23904896
PMC: 3425695.
DOI: 10.1007/s11832-012-0421-3.
Congenital pseudarthrosis of the tibia: Management and complications.
Shah H, Rousset M, Canavese F
Indian J Orthop. 2013; 46(6):616-26.
PMID: 23325962
PMC: 3543877.
DOI: 10.4103/0019-5413.104184.
Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia.
Birke O, Schindeler A, Ramachandran M, Cowell C, Munns C, Bellemore M
J Child Orthop. 2011; 4(6):507-17.
PMID: 22132028
PMC: 2981713.
DOI: 10.1007/s11832-010-0293-3.
Enhancement of difficult nonunion in children with osteogenic protein-1 (OP-1): early experience.
Dohin B, Dahan-Oliel N, Fassier F, Hamdy R
Clin Orthop Relat Res. 2009; 467(12):3230-8.
PMID: 19588211
PMC: 2772942.
DOI: 10.1007/s11999-009-0967-7.
